Growth Hormone Peptide Safety
Safety considerations for unapproved growth hormone-releasing peptides. Learn why caution is warranted with these research compounds.
Safety Overview
Growth hormone (GH) axis secretagogues sold as “research compounds” — CJC-1295, ipamorelin, GHRP-2, GHRP-6, hexarelin — hold no regulatory approval for physique or performance indications. A 2026 structured narrative review in JBJS Reviews places this class as “investigational, with uncertain safety profiles, product quality concerns, and widespread antidoping restrictions.”
A 2026 Sports Medicine review of the same market reaches a parallel conclusion: many of these unapproved peptides show favourable outcomes in animal models, but “rigorous human safety data are scarce, and there is potential for serious harm to patients.”
Regulatory Status
| Peptide | Status |
|---|---|
| Ipamorelin | No FDA approval; classed as investigational |
| CJC-1295 (with and without DAC) | No FDA approval; classed as investigational |
| GHRP-6 | No FDA approval; sold through unregulated supply chains |
| Sermorelin | Was FDA-approved as GEREF (NDA 019863); Drugs@FDA lists it discontinued |
| Tesamorelin | FDA-approved as EGRIFTA / EGRIFTA SV for a specific HIV indication |
The 2026 Frontiers in Endocrinology review separates these into distinct classes: sermorelin, tesamorelin, and CJC-1295 are grouped as GHRH analogues, while GHRP-2, GHRP-6, hexarelin, and ipamorelin are grouped as growth hormone secretagogues. Approval of one member of the class says nothing about the safety of the others.
What the Approved Label Documents
Tesamorelin is the one GH-axis peptide in this group with a full FDA label, so its label is the best available human record of what raising GH and IGF-1 does. The EGRIFTA SV prescribing information carries these warnings and precautions:
- Fluid retention — the label states it “may include edema, arthralgia, and carpal tunnel syndrome”
- Glucose intolerance or diabetes mellitus — “may develop with EGRIFTA SV use”
- Elevated IGF-1 — “The effects of prolonged elevations in IGF-1 levels are unknown.” Among patients treated for 26 weeks, 47% had IGF-1 above 2 standard deviation scores and 36% above 3
- Increased risk of neoplasms — active malignancy is a contraindication
- Hypersensitivity reactions and injection site reactions
- Increased mortality in patients with acute critical illness
Most commonly reported adverse reactions (>5%) on that label: arthralgia, injection site erythema, injection site pruritus, pain in extremity, peripheral edema, and myalgia.
These are documented for an approved product under monitored conditions. They are not a measured safety profile for ipamorelin, CJC-1295, or GHRP-6, which have no equivalent record.
Reported Effects of the Unapproved Peptides
The 2026 Frontiers in Endocrinology review of GH-IGF-1 axis performance peptides reports adverse effects spanning “endocrine and metabolic disturbances (including prolactin and cortisol elevations, appetite changes, and dysglycaemia), fluid retention syndromes, musculoskeletal symptoms (myalgia/arthralgia), and injection-site reactions.”
That review stratifies these peptides into evidence tiers running from regulatory-grade randomized trial data down to a complete absence of human studies. Where a peptide sits in that range is the single most useful thing to know about it.
Product Quality
The same review names “uncertainty surrounding product composition, dose, and stacking practices in unregulated supply chains” as a core reason clinicians cannot interpret symptoms in people using these compounds. Product quality concerns are also listed explicitly in the JBJS Reviews assessment of this class.
Antidoping
The JBJS Reviews narrative review records “widespread antidoping restrictions” on GH axis secretagogues including CJC-1295, ipamorelin, and tesamorelin. Athletes subject to testing should confirm current status with their own governing body, since prohibited lists are revised annually.
What the Reviews Recommend
The JBJS Reviews authors conclude that clinical use “should be confined to approved metabolic agents for indicated conditions and to rigorously designed research protocols,” and that clinicians should counsel patients about uncertain efficacy, product quality, safety risks, and antidoping implications.
This safety information is for educational purposes and is not medical advice. Most peptides discussed here are not FDA-approved. Discuss any health decision with a qualified clinician.
Sources & Citations
- 4
- 5
Disclaimer: This article is for educational purposes only and does not constitute medical advice. The information presented is based on current research but should not be used for diagnosis, treatment, or prevention of any disease. Always consult a qualified healthcare provider before making health decisions.